Cell therapy weekly: US FDA clears cell therapy for Phase I trial in patients with advanced Parkinson’s disease
This week: the US FDA has cleared an IND application for a cell therapy candidate to proceed with a Phase I study in patients with advanced Parkinson’s disease, a cryopreserved amniotic suspension allograft for knee osteoarthritis receives RMAT designation, and Capricor enters a collaboration with Lonza to develop its cell therapy candidate for Duchenne muscular dystrophy. The news highlights: US FDA clears cell therapy for Phase I trial in patients with advanced Parkinson’s disease ReNu® receives RMAT for the management of symptoms associated with knee osteoarthritis Lonza and Capricor collaborate to develop cell therapy candidate for Duchenne muscular dystrophy ...